Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, Single-center, Phase Ib Study Assessing IBI308 Monotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

Trial Profile

Open, Single-center, Phase Ib Study Assessing IBI308 Monotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2022 Results of three year follow up published in the Journal of Thoracic Oncology
    • 06 Feb 2020 Results evaluating the safety and outcome of PD-1 inhibitor in neoadjuvant setting published in the Journal of Thoracic Oncology
    • 10 Sep 2019 Results (data cut off: June 15th, 2019) assessing the safety and efficacy of neoadjuvant sintilimab in Chinese patients with resectable NSCLCpresented at the 20th World Conference on Lung Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top